PMID: 21495876
Title: How can HIV type 1 Env immunogenicity be improved to facilitate antibody based vaccine development
Abstract: No vaccine candidate has induced antibodies (Abs) that efficiently neutralize multiple primary isolates of HIV-1. Preexisting high titers of neutralizing antibodies (NAbs) are essential, because the virus establishes infection before anamnestic responses could take effect. HIV-1 infection elicits Abs against Env, Gag, and other viral proteins, but of these only a subset of the anti-Env Abs can neutralize the virus. Whereas the corresponding proteins from other viruses form the basis of successful vaccines, multiple large doses of HIV-1 Env elicit low, transient titers of Abs that are not protective in humans. The inaccessibility of neutralization epitopes hinders NAb induction, but Env may also subvert the immune response by interacting with receptors on T cells, B cells, monocytes, macrophages, and dendritic cells. Here, we discuss evidence from immunizations of different species with various modified Env constructs. We also suggest how the divergent Ab responses to Gag and Env during infection may reflect differences in B cell regulation. Drawing on these analyses, we outline strategies for improving Env as a component of a vaccine aimed at inducing strong and sustained NAb responses.
Date: 1970-08-21
Year: 2012
Journal: AIDS Res. Hum. Retroviruses
PMID Author: Klasse PJ, Sanders RW, Cerutti A, Moore JP
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res. Hum. Retroviruses 2012;28(1):1-15 doi: 10.1089/AID.2011.0053

Media Contacts


Ethel Makila
+254 71 904 3142 



Hester Kuipers
+31 20 521 0343 



Saif ul Hadi
+91 11 4737 6032 


North America

Rose Catlos
+1 212 847 1049